Core Insights - Tempus AI has initiated partnerships with leading academic medical centers, including NYU Langone Health and Northwestern Medicine, to enhance access to advanced genomic testing and data-driven cancer care [2][4]. Group 1: Partnerships and Collaborations - The collaboration with NYU Langone Health focuses on improving genetic diagnostics and accelerating the development of new tests and data-driven tools [2][3]. - Tempus is expanding its role in next-generation sequencing (NGS) testing to include test validation, biomarker discovery, disease modeling, and AI-driven prediction tools [3]. - The partnership with Northwestern Medicine aims to provide nearly all cancer patients, including those diagnosed at early stages, access to genetic testing [4][5]. Group 2: Testing and Treatment - Tempus will support Northwestern Medicine by offering a variety of genomic tests, including tissue testing, DNA and RNA profiling, liquid biopsy, and minimal residual disease (MRD) testing [5]. - These genomic tests are designed to help doctors understand each patient's cancer better and select more personalized and effective treatments [5]. Group 3: Market Performance - Tempus' stock has increased by 114.3% over the past year, significantly outperforming the industry growth of 4.3% and the S&P 500's 22% increase during the same period [8]. Group 4: Valuation Metrics - Tempus currently trades at a forward 12-month Price-to-Sales (P/S) ratio of 7.84X, which is higher than the industry average of 5.77X [10]. Group 5: Earnings Estimates - The loss per share estimate for Tempus AI for 2025 has narrowed by 1 cent to 64 cents over the past 30 days [11].